Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT).

[1]  M. Tan,et al.  Targeted therapy for renal cell carcinoma: The next lap , 2014, Journal of carcinogenesis.

[2]  T. Trikalinos,et al.  Table 2, American Society of Anesthesiologists (ASA) physical status classification system , 2014 .

[3]  J. Dutcher.  Recent developments in the treatment of renal cell carcinoma , 2013, Therapeutic advances in urology.

[4]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[5]  M. Milella,et al.  Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives , 2013, Expert review of anticancer therapy.

[6]  A. Minervini,et al.  Management of localized and locally advanced renal tumors. A contemporary review of current treatment options. , 2013, Minerva medica.

[7]  G. Sonpavde,et al.  Optimal Management of Metastatic Renal Cell Carcinoma: Current Status , 2013, Drugs.

[8]  B. Escudier,et al.  Emerging immunotherapies for renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  C. Porta,et al.  Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. , 2012, European journal of cancer.

[10]  N. Tannir,et al.  Treatment of patients with metastatic renal cell carcinoma (RCC) and end-stage renal disease (ESRD) with targeted therapy (TT): A case series. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[12]  C. Porta,et al.  7114 POSTER DISCUSSION Appropriateness of Treatment Options for the Management of Patients With Advanced Renal Cell Carcinoma (RCC) Using the Validated Semi Quantitative RAND Corporation/University of California, Los Angeles (RAND/UCLA) Methodology , 2011 .

[13]  R. Figlin,et al.  Treatment of patients with metastatic renal cell cancer , 2006, Cancer.